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ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is the most
common form of fibrosing idiopathic
interstitial pneumonia. The disease, which
primarily occurs in older adults, is inexorably
progressive with a 5-year survival of
approximately 20%. Improved understanding
of disease pathobiology has affected the
approach to treatment. Indeed, originally
thought to be a chronic inflammatory
disorder, IPF is now considered the result of
persistent alveolar epithelial micro-injury
followed by an aberrant repair response. This
paradigm shift along with significant
improvement in disease definition and patient
stratification has led to an exponential increase
in the number of high-quality clinical trials,
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most of which, however, have produced
negative results, probably due to the multitude
of cell types, growth factors and signaling
pathways involved in the fibrotic process.
Therefore, until recently IPF has lacked
effective therapies. Finally, in 2014,
pirfenidone, a compound with broad
antifibrotic, anti-inflammatory and
antioxidant properties and nintedanib, an
orally available, small-molecule tyrosine kinase
inhibitor with selectivity for vascular
endothelial growth factor, platelet-derived
growth factor and fibroblast growth factor
receptors, have shown to significantly slow
functional decline and IPF disease progression
with an acceptable safety profile. This is a major
step forward. However, neither pirfenidone nor
nintedanib is a cure for IPF; neither drug
improves lung function and the disease
continues to progress in most patients despite
treatment. A number of agents with high
potential are currently being tested and many
more are ready for clinical trials. Their
completion is critical for achieving the
ultimate goal of curing this devastating disease.
Keywords: Guidelines; Idiopathic pulmonary
fibrosis; Nintedanib; Pirfenidone; Therapy;
Treatment; Usual interstitial pneumonia
DISEASE OVERVIEW
Idiopathic pulmonary fibrosis (IPF) is the most
common form of chronic, progressive, fibrosing
interstitial pneumonia [1]. The disease, which
occurs primarily in older adults, is limited to the
lungs and is associated with the radiological
and/or histopathologic pattern of usual
interstitial pneumonia (UIP) [2, 3].
Radiological UIP is characterized on
high-resolution computed tomography (HRCT)
by the presence of reticular opacities, often
associated with traction bronchiectasis,
typically in a basal, subpleural and patchy
distribution [4]. However, a definite diagnosis
of UIP on HRCT requires the presence of
honeycombing, which manifests as clustered
cystic airspaces, usually of comparable diameter
on the order of 3–10 mm (Fig. 1) [5].
Histopathologic UIP consists of a combination
of fibrotic areas with scarring and honeycomb
change alternate with areas of less affected or
even normal lung parenchyma (Fig. 2). The
fibrotic zones are composed mainly of dense
collagen, although scattered subepithelial foci
of proliferating fibroblasts and myofibroblasts
(so-called fibroblastic foci) are a consistent
finding. Notably, a pattern of UIP can be
found in a number of conditions including,
among others, connective tissue disease (CTD),
chronic hypersensitivity pneumonitis (HP) and
pneumoconioses (especially asbestosis), which
makes it essential a rigorous and
multidisciplinary approach to the diagnosis of
IPF (e.g., idiopathic UIP) [6]. This point remains
unappreciated by many physicians, and, as a
Fig. 1 Usual interstitial pneumonia pattern. Chest
high-resolution computed tomography showing reticular
abnormality in a typical subpleural distribution. Areas with
honeycombing (arrow) are also seen
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result, patients are often incompletely evaluated
and empirically treated as IPF.
Incidence and prevalence of IPF increase
dramatically with age. Indeed, the disease is
virtually absent in patients younger than
50 years of age, but is present in an estimated
0.2% of those older than 75 years of age [7, 8].
The underlying causes of the fibrotic response
in IPF remain unknown. However, cigarette
smoking, exposure to metal and wood dust,
microbial agents, chronic microaspiration
secondary to gastro-oesophageal reflux and
genetic abnormalities have all been associated
with an increased risk of developing the disease
[9–13]. Consistent with the progressive nature
of the fibrotic process, shortness of breath on
exertion is the most common presenting
symptom. IPF is almost invariably fatal with a
5-year survival of approximately 20% and a
mortality burden higher than that of many
cancers [14]. Yet, its clinical course and rate of
progression are highly variable and
unpredictable. In fact, periods of relative
stability may be punctuated by episodes of
accelerated deterioration, so-called ‘acute
exacerbations’ often resulting in respiratory
failure and death [15, 16]. Moreover, a
subgroup of patients, predominantly smoking
males, display an accelerated clinical course and
have a gene expression pattern that is different
from those with slower progression and longer
survival [17].
Our understanding of IPF has undergone
dramatic change in the last two decades, and
this has affected the approach to treatment.
Indeed, older pathogenetic models of chronic
active inflammation leading to fibrosis have
evolved to current models of repeated alveolar
epithelial cell micro-injury and dysregulated
repair response in the presence of relatively
little inflammation [18]. According to the
abnormal repair response hypothesis, key
pathogenetic events include uncontrolled
proliferation of lung fibroblasts and
differentiation of fibroblasts into
myofibroblasts, which excessively deposit
extracellular matrix (ECM) proteins in the
interstitial space leading to progressive scarring
of the lung, architectural distortion and
irreversible loss of function [19–21]. As a
result, more recent clinical trials of
pharmacological interventions have evaluated
the efficacy of molecules targeting the wound
healing cascade and fibrogenesis, although,
overall, with disappointing results, probably
because of the multitude of mediators, growth
factors and signaling pathways involved in the
fibrotic process [22]. Finally, more recently, two
compounds with pleiotropic mechanisms of
Fig. 2 Surgical lung biopsy specimen showing usual
interstitial pneumonia, characterized by the abrupt tran-
sition from dense ﬁbrosis (top right and bottom left) to
nearly normal lung (center). Hematoxylin-eosin, 209.
Courtesy of Giulio Rossi, MD, Modena, Italy
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action—pirfenidone and nintedanib—have
consistently proven effective in reducing
functional decline and disease progression in
patients with IPF [23, 24]. In this article we
summarize the evidence supporting the efficacy
of pirfenidone and nintedanib in IPF and
provide an overview of clinical drug
development in this devastating disease. This
article is based on previously conducted studies
and does not involve any new studies of human




The management of patients with IPF is largely
based on the recommendations of the
guidelines developed by the American
Thoracic Society (ATS)/European Respiratory
Society (ERS)/Japanese Respiratory Society
(JRS)/Latin American Thoracic Association
(ALAT) [2]. This evidence-based document,
which was published in 2011, has recently
been updated to incorporate reappraisal of
previously evaluated treatment options and
recommendations on novel agents [25]. For
each outcome of interest, a multidisciplinary
panel assessed the overall certainty (e.g., the
confidence) in effect estimate according to the
GRADE (Grading of Recommendations
Assessment, Development and Evaluation)
methodology [26], which is based on the
following criteria: risk of bias, precision,
consistency, directness of the evidence, risk for
publication bias, presence of dose–effect
relationship, magnitude of effect, and
assessment of the effect of plausible residual
confounding or bias. The confidence in effect
estimates for each outcome was graded as high,
moderate, low, or very low [25]. In addition, for
any given question, the multidisciplinary
committee made a recommendation for or
against [27]. The recommendations were either
‘strong’ or ‘conditional’, based on the following
factors: quality and strength of evidence,
outcomes and associated importance to
patients, desirable and undesirable
consequences of treatment, costs, implications
of treatment on health equity, feasibility of
treatment, the acceptability of treatment to
stakeholders and implementation issues.
Current recommendations are summarized in
Table 1.
Three treatment interventions, which are
discussed in the following sections, received a
conditional recommendation for use (e.g.,
pirfenidone, nintedanib, and antiacid
medication), although the committee
emphasized that recommendations with the




one) is an orally available, synthetic,
non-peptide, low molecular weight molecule
with anti-fibrotic, anti-inflammatory and
anti-oxidant properties [28]. Pirfenidone’s
biological actions include inhibition of the
synthesis and activity of transforming growth
factor (TGF)-b; inhibition of fibroblast
proliferation and collagen secretion; reduction
of pro-fibrotic gene expression in response to
fibrotic stimuli; and inhibition of
pro-inflammatory cytokine (mainly tumor
necrosis factor [TNF]-a) production and release
[29–32].
Following promising results from an
open-label trial [33], safety and efficacy of
pirfenidone in patients with IPF were initially
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evaluated in a phase 2 double-blind,
placebo-controlled, multicenter study
conducted in Japan by Azuma et al. [34]. This
trial was stopped prematurely following an
interim analysis revealing that episodes of
acute exacerbation of IPF (AE-IPF) had
occurred exclusively in the placebo arm (n = 5;
14% vs. 0% in the pirfenidone arm; P = 0.0031)
during the 9-month study period. The change
in the lowest oxygen saturation (SpO2) during a
6-min exercise test (6MET), the primary
endpoint, did not reach statistical significance
(P = 0.0722). However, in a pre-specified
analysis of patients who maintained a
SpO2[80% during a 6MET at baseline, the
lowest SpO2 during a 6MET improved in the
pirfenidone group at 6 and 9 months
(P = 0.0069 and P = 0.0305, respectively).
Positive treatment effects were also
demonstrated in the change in vital capacity
(VC) at 9 months (P = 0.0366). Following these
promising data, Taniguchi and colleagues
conducted a multicenter, double-blind,
placebo-controlled phase three study in which
275 Japanese patients were randomized in a
2:1:2 ratio to high-dose (1800 mg/day) or
low-dose (1200 mg/day) pirfenidone, or
placebo [35]. The study met its primary
endpoint of change in VC from baseline to
week 52. In fact, the rate of decline of VC was
lower in both the high-dose (-0.09 L) and
low-dose pirfenidone arms (-0.08 L) compared
to the placebo arm (-0.16 L; P = 0.042 and
P = 0.039, respectively). Significant differences
Table 1 Overview of recommendations in the 2015 and 2011 IPF guidelines
Agent/intervention 2015 guidelines 2011 guidelines
Nintedanib Conditional recommendation for usea Not addressed
Pirfenidone Conditional recommendation for usea Conditional recommendation against useb
Antiacid therapy Conditional recommendation for usec Conditional recommendation for usea
Bosentan, macitentan Conditional recommendation against useb Strong recommendation against usea
NAC monotherapy Conditional recommendation against useb Conditional recommendation against useb
Sildenaﬁl Conditional recommendation against usea Not addressed
Ambrisentan Strong recommendation against useb Not addressed
Combination prednisone,
azathioprine and NAC
Strong recommendation against useb Conditional recommendation against useb
Imatinib Strong recommendation against usea Not addressed
Warfarin Strong recommendation against usea Conditional recommendation against usec
Therapy for IPF-associated PH Reassessment of the previous
recommendation was deferred
Conditional recommendation against usec
Lung transplantation: single
versus bilateral




IPF Idiopathic pulmonary ﬁbrosis, NAC N-acetylcysteine, PH Pulmonary hypertension
a Moderate conﬁdence in effect estimates
b Low conﬁdence in effect estimates
c Very low conﬁdence in effect estimates
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were also observed in progression-free survival
time (defined as time to death and/or C10%
decline in VC from baseline) between the
high-dose and the placebo arms (P = 0.028)
and in change in total lung capacity (TLC)
between the low-dose and the placebo arms
(P = 0.040). However, a limitation of this study
was that the primary endpoint was changed
before unblinding, which possibly hampered
the integrity of the study. Overall, pirfenidone
was well tolerated. The most common
drug-related adverse event was
photosensitivity (observed in 51% of patients
in the high-dose group and 53% in the low-dose
group), which was mild in severity in most cases
and not a major reason for discontinuation of
the study. Pirfenidone was approved in Japan
for use in patients with IPF in 2008.
The CAPACITY (Clinical Studies Assessing
Pirfenidone in IPF: Research on Efficacy and
Safety Outcomes; ClinicalTrials.gov identifiers,
NCT00287729 and NCT00287716) program
consisted of two almost identical randomized,
double-blind, placebo-controlled, multinational
phase 3 trials (PIPF-004 and PIPF-006) that
involved 110 centers across Europe, North
America, Mexico, and Australia [36]. Both trials
enrolled patients aged 40–80 years with a
diagnosis of IPF made within the previous
48 months based on clinical, radio-logic and/or
pathologic data, and according to the 2000 ATS/
ERS guidelines [1]. Inclusion criteria included
also predicted forced VC (FVC) of at least 50%,
predicted diffusing capacity of the lung for
carbon monoxide (DLCO) of at least 35%,
either predicted FVC or predicted DLCO of 90%
or less, and 6-min walk test distance (6MWD) of
at least 150 m. In study 004, 435 patients were
assigned in a 2:1:2 dosing ratio to pirfenidone
2403 mg/day (n = 174), pirfenidone
1197 mg/day (n = 87), or placebo (n = 174),
whereas study 006 had only two arms (i.e.,
pirfenidone 2403 mg/day, n = 173 and placebo,
n = 171). Pirfenidone was administered daily
with food in three divided doses and titrated up
to the full dose over 2 weeks. The primary
endpoint of both studies was change in
percentage predicted FVC from baseline to
week 72 and efficacy analyses, which were
performed in the intent-to-treat population,
used a rank analysis of covariance (ANCOVA)
model. In PIPF-004, pirfenidone reduced decline
in FVC. In fact, mean FVC change at week 72
was -8.0% in the pirfenidone 2403 mg/day
group and -12.4% in the placebo group
(P = 0.001), whereas in the pirfenidone
1197 mg/day arm, the primary outcome was
intermediate to that of the pirfenidone
2403 mg/day and placebo arms. In addition,
35 of 174 (20%) patients in the pirfenidone arm
and 60 of 174 (35%) in the placebo arm had an
FVC decline of at least 10% (P = 0.001). By
contrast, in study 006, the between-group
difference in FVC change at week 72 was not
significant (P = 0.501), although, a consistent
pirfenidone effect was apparent until week 48
(P = 0.005) and in an analysis of all study time
points (P = 0.007). Mean change in percentage
predicted FVC was -9.0% in the pirfenidone
arm and -9.6% in the placebo arm. Most
common pirfenidone-related adverse events
included nausea (36% vs. 17% in placebo),
dyspepsia (19% vs. 7%), vomiting (14% vs.
4%), anorexia (11% vs. 4%), photosensitivity
(12% vs. 2%), skin rash (32% vs. 12%), and
dizziness (18% vs. 10%). However, they were
generally mild to moderate in severity,
reversible, and without clinically significant
sequelae. These trials had sufficient
methodological quality to be included in a
Cochrane meta-analysis that showed that
pirfenidone significantly reduces the rate of
functional decline and risk of disease
progression compared with placebo [37].
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In 2011, pirfenidone has been approved for
the treatment of IPF in Europe, but not by the
US Food and Drug Administration (FDA), which
requested an additional phase 3 study to
confirm efficacy. In the ASCEND (Assessment
of Pirfenidone to Confirm Efficacy and Safety in
IPF; ClinicalTrials.gov identifier, NCT01366209)
study, 555 patients with IPF were randomly
assigned to receive either pirfenidone
2403 mg/day (n = 278) or placebo (n = 277) for
52 weeks [23]. Of note, to enroll patients at
higher risk for disease progression, certain
aspects of the CAPACITY study design were
modified such as exclusion of patients with
major airflow limitation (ratio of the forced
expiratory volume in one second (FEV1) to
FVC\0.80) and reduction of the minimum
baseline DLCO from 35% to 30% of the
predicted value. With regard to the HRCT
diagnostic criteria for inclusion, only a definite
UIP pattern was accepted. The study met its
primary outcome of change from baseline to
week 52 in the percentage of predicted FVC. In
addition, a significant relative reduction of
47.9% in the proportion of patients who had
an absolute decline of C10% in percentage
predicted FVC or who died [46 patients
(16.5%) vs. 88 patients (31.8%); P\0.001],
and a significant relative increase of 132.5% in
the proportion of patients with no decline in
FVC [63 patients (22.7%) vs. 27 patients (9.7%);
P\0.001] was seen in the pirfenidone
compared to the placebo arm. A series of
sensitivity analyses confirmed the robustness
of these findings and the estimated magnitude
of pirfenidone effect (e.g., an approximate 50%
reduction in FVC decline) in patients with IPF
[38]. Pirfenidone treatment reduced also the
decline in the 6MWD (P = 0.04) and improved
progression-free survival (e.g., time to the first
occurrence of any one of the following: a
confirmed decrease of C10% in the percentage
of the predicted FVC, a confirmed decrease of
50 m or more in the 6MWD, or death;
P\0.001). No significant differences between
pirfenidone and placebo were found in dyspnea
scores (P = 0.16) or in all-cause (4.0% vs. 7.2%;
P = 0.10) or IPF-related mortality (1.1% vs.
2.5%; P = 0.23). However, a pre-specified
pooled analysis from the ASCEND and
CAPACITY trials showed that pirfenidone
significantly reduced both death from any
cause [3.5% vs. 6.7 %; hazard ratio (HR) 052;
P = 0.01] and from IPF (1.1% vs. 3.5 %; HR 0.32;
P = 0.006) compared with placebo at week 52.
Similar to the CAPACITY trials, gastrointestinal
and skin-related events were more common in
the pirfenidone group than in the placebo
group, although they were generally mild to
moderate in severity, reversible, and without
clinically significant sequelae. Moreover, the
proportion of adverse events leading to
discontinuation of study treatment did not
differ between the pirfenidone (40 patients;
14.4%) and the placebo groups (30 patients;
10.8%).
Recommendations on optimal management
of pirfenidone-related adverse events based on
existing guidelines, research evidence, and expert
opinion have recently been published [39]. In
October 2014 the FDA granted pirfenidone fast
track, priority review, orphan product, and
breakthrough designation. Several reports have
confirmed long-term favorable safety and efficacy
profiles of pirfenidone [40–42]. In particular, an
interim analysis of RECAP, an ongoing
open-label, long-term, follow-up extension
study that included patients who completed the
CAPACITY or ASCEND trials, showed that almost
50% of the patients initially randomized to
pirfenidone were still receiving therapy after
5-year follow-up [41].
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NINTEDANIB
Nintedanib is a potent inhibitor of the receptor
tyrosine kinases vascular endothelial growth
factor receptor (VEGFR) 1–3, fibroblast growth
factor receptor (FGFR) 1–3, and platelet-derived
growth factor receptor (PDGFR) a and b [43]. By
competitively and reversibly inhibiting the
adenosine triphosphate binding pocket of the
receptor tyrosine kinases VEGFR, FGFR, and
PDGFR, nintedanib blocks the intracellular
signaling needed for the proliferation,
migration and transformation of fibroblasts
[44, 45]. However, it has been recently shown
that antifibrotic properties of nintedanib also
include: inhibition of TGF-b
receptor(s) signaling; inhibition of fibronectin
and collagen 1a1 mRNA expression
independent of TGF-b signaling; and
induction of non-canonical autophagy [46].
The safety and efficacy of oral nintedanib in
patients with IPF were initially evaluated in the
TOMORROW (To Improve Pulmonary Fibrosis
With BIBF 1120; ClinicalTrials.gov identifier,
NCT00514683), a phase 2, dose-finding,
12-month, randomized, double-blind,
placebo-controlled trial [47]. Inclusion criteria
included age C40 years, IPF diagnosed within
the previous 5 years, FVC of C50% of predicted
value, DLCO of 30–79% of predicted value, and
HRCT of the chest performed within the
previous 12 months. In the TOMORROW trial,
four different doses of nintedanib were tested
[i.e., 50 mg once a day (n = 86), and 50 mg
(n = 86), 100 mg (n = 86), or 150 mg (n = 85) all
twice a day] against placebo (n = 85).
Nintedanib showed a trend towards a
reduction in the annual rate of decline in FVC,
the primary endpoint. Specifically, the adjusted
annual rate of decline in FVC was 0.06 L/year in
the group receiving nintedanib 150 mg twice
daily and 0.19 L/year in the placebo group
corresponding to a reduction of 68.4% in the
rate of FVC loss [P = 0.06 using a closed testing
procedure for multiplicity correction (primary
analysis) and P = 0.01 using hierarchical
testing, both pre-specified] [47]. In addition,
compared with placebo, significantly fewer
patients in the nintedanib 150 mg twice daily
group had a decline in mean FVC of C10% or
C200 mL (23.8% vs. 44.0%, respectively;
P = 0.004). The highest dose of nintedanib was
also associated with a lower incidence of AE-IPF
(2.4 vs. 15.7 per 100-patient-years; risk ratio:
0.16; P = 0.02) and an improved quality of life
as assessed by St. George’s Respiratory
Questionnaire (SGRQ; -0.66 vs. ?5.46 points;
P = 0.007) compared with placebo. Overall,
nintedanib showed an acceptable safety
profile. The most frequent adverse event in the
group receiving 150 mg nintedanib twice daily
was diarrhea (55.3% vs. 15.3% in the placebo
group), followed by nausea (23.5% vs. 9.4%)
and vomiting (12.9% vs. 4.7%). The adverse
events most frequently leading to
discontinuation were also diarrhea, nausea,
and vomiting, but the proportion of patients
who discontinued the study medication
because of adverse events did not differ
between the nintedanib 150 mg twice daily
group and the placebo group. Clinically
significant elevations in liver enzyme levels
(e.g., at least three times the upper limit of the
normal range for aspartate aminotransferase or
alanine aminotransferase at any time after
baseline) were observed in 6 patients in the
group receiving 150 mg of nintedanib twice a
day (7.1%) and none in the placebo group;
however, only two patients discontinued the
study medication because of persistently
abnormal liver function tests.
The INPULSIS (INPULSIS-1 and INPULSIS-2;
ClinicalTrials.gov identifiers, NCT01335464
and NCT01335477, respectively) trials were
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two parallel 52-week, randomized,
double-blind, placebo-controlled, phase three
studies designed to confirm the efficacy and
safety of nintedanib 150 mg twice daily in
patients with IPF [24]. The eligibility criteria
for patients with IPF were identical to those of
the TOMORROW trial. A total of 1066 patients
were randomized 3:2 to receive nintedanib
150 mg twice daily (n = 309 in INPULSIS-1 and
n = 329 in INPULSIS-2) or placebo (n = 204 in
INPULSIS-1 and n = 219 in INPULSIS-2). In both
trials, nintedanib significantly reduced the rate
of decline in FVC over the 52-week study period
(the primary end point). Indeed, the adjusted
annual rate of change in FVC was -114.7 mL in
the nintedanib arm and -239.9 mL in the
placebo arm in INPULSIS-1 (between-group
difference: 125.3 mL; P\0.001) and -113.6
and -207.3 mL in INPULSIS-2 (between-group
difference: 93.7 mL; P\0.001), respectively.
Pre-specified sensitivity analyses confirmed the
robustness of the results of the primary analysis.
Moreover, in both trials, patients in the
nintedanib arm were more likely than those in
the placebo arm to be stable at week 52 (e.g., to
have a decline in percentage predicted FVC of
no greater than 5%; 52.8% vs. 38.2% in
INPULSIS-1, P = 0.001; and 53.2% vs. 39.3% in
INPULSIS-2, P = 0.001). Overall, the risk of
progression (e.g., absolute decline in percent
predicted FVC of C10% or death) was
significantly reduced with nintedanib versus
placebo by 47% in INPULSIS-1 (24.3% vs.
40.7%; HR 0.53; P = 0.0001), 33% in
INPULSIS-2 (29.8% vs. 42.0%; HR 0.67;
P = 0.0054) and 40% in the pooled analysis
(27.1% vs. 41.4%; HR 0.60; P\0.0001) [45]. As
for the two key secondary end points (i.e., the
time to the first AE-IPF as reported by a site
investigator and the change from baseline in
the total score on the SGRQ), the two trials
provided mixed results. In fact, the time to the
first AE-IPF was significantly increased in
INPULSIS-2 (HR 0.38, P = 0.005), but not in
INPULSIS-1 (HR 1.15, P = 0.67). However, a
pre-specified sensitivity analysis of pooled data
from INPULSIS-1 and INPULSIS-2 showed that
the time to first adjudicated AE-IPF (confirmed
or suspected) was significantly increased with
nintedanib compared to placebo (HR 0.32,
P = 0.001). In INPULSIS-2, at week 52 there
was a significantly smaller increase in the total
SGRQ score (consistent with less deterioration
in health-related quality of life) in the
nintedanib group than in the placebo group
(2.80 points in the nintedanib group vs. 5.48
points in the placebo group; P = 0.02), whereas
in INPULSIS-1 there was no significant
between-group difference in the adjusted
mean change in the SGRQ total score from
baseline to week 52 (4.34 points vs. 4.39 points;
P = 0.97). Similarly, in a pre-specified pooled
analysis of the two trials, the adjusted mean
change from baseline in the SGRQ total score
did not significantly differ between the
nintedanib and placebo arms. In a
pre-specified pooled analysis, there was no
significant between-group difference in death
from any cause (5.5% vs. 7.8%; HR 0.70;
P = 0.14) or death from a respiratory cause
(3.8% vs. 5.0%; HR: 0.74; P = 0.34). Of note,
subgroups analyses of pooled data from the
INPULSIS trials showed that sex, age (\65,
C65 years), race (White, Asian), baseline FVC
% predicted (B70%,[70%), baseline SGRQ total
score (B40, [40), smoking status (never, ex/
current), systemic corticosteroid use (yes, no),
and bronchodilator use (yes, no) did not
influence the efficacy of nintedanib on the
decline in FVC over 52 weeks [48]. Similar to
the TOMORROW trial, the most frequent
adverse event in the nintedanib groups in
both INPULSIS-1 and INPULSIS-2 was diarrhea
(approximately 60% within the first 3 months
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of treatment), which overall led to premature
discontinuation in 4.4% of patients in the
nintedanib group [49]. However, in both trials,
the proportion of patients with serious adverse
events was similar in the nintedanib and
placebo groups.
Similar to pirfenidone, in October 2014
nintedanib has been granted fast track,
priority review, orphan product, and
breakthrough designation by the FDA, and has
been licensed in Europe in early 2015.
ANTIACID THERAPY
Gastroesophageal reflux (GER), including
clinically silent GER, is highly prevalent in
patients with IPF [50, 51], and markers of
aspiration (e.g., bile acids and pepsin) are
significantly elevated in bronchoalveolar
lavage fluid (BALF) from patients with IPF
compared to patients with interstitial lung
disease other than IPF and healthy controls
[52]. In addition, levels of inflammatory
biomarkers such as lactate dehydrogenase,
alkaline phosphatase, C-reactive protein, and
TNF-a are higher in BALF of patients with
newly diagnosed IPF compared to patients
with newly diagnosed GER disease [53].
Chronic microaspiration secondary to GER
is considered a risk factor for the
development or worsening of the disease,
suggesting that prevention of microaspiration
could have an important role in the
management of IPF.
In an uncontrolled retrospective study of 204
patients with IPF, antiacid treatment (AAT) was
associated with reduced radiological fibrosis and
was an independent predictor of longer survival
time [54]. In addition, a post hoc analysis of
data from patients assigned to placebo arms in
three IPFnet-sponsored randomized-controlled
trials (RCTs) revealed that patients taking AAT
at baseline [either proton-pump inhibitors or H2
blockers; n = 124/242 (51%)] had a smaller
decrease in FVC at 30 weeks compared with
those not taking AAT (P = 0.05) after adjusting
for sex, baseline percentage predicted FVC, and
baseline percentage predicted DLCO [55]).
However, a more recent post hoc analysis of
patients in the placebo arms of three large RCTs
[n = 624, 291 of whom (47%) were taking AAT
at baseline] showed that AAT did not improve
progression-free survival (defined as FVC
decrease C10%, 6MWD decrease C50 m, or
death), FVC decline, hospitalization and
all-cause and IPF-related mortality, but was
associated with a significantly higher rate of
all-cause hospitalization (HR 1.4, P = 0.042)
[56]. Despite the lack of evidence from
prospective RCTs, the 2015 guidelines
recommend AAT for most patients with IPF
based on the potential benefit and the favorable
side effect profile of antiacid medications [25].
However, further research focusing on efficacy




Historically, the pharmaceutical industry has
been reluctant to invest in research and
development of drugs for rare diseases like IPF
[57]. The last decade has witnessed a growing
interest in IPF and a willingness among
stakeholders to work together to develop and
fund clinical trials of novel compounds. In
addition, improved understanding of disease
pathogenesis has resulted in an exponentially
increasing number of potential therapeutic
targets. Selected most developed compounds
for IPF are listed below.
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PRM-151
PRM-151 (Promedior, Inc, Lexington, MA, USA)
is a recombinant form of an endogenous
human protein, pentraxin-2 (PTX-2), that is
specifically active at the site of tissue damage.
PRM-151 is an agonist that binds to Fc-gamma
receptors on monocytes and induces their
differentiation into regulatory (pro-resolutive)
macrophages, thus promoting epithelial
healing and resolution of inflammation and
scarring. In a multiple ascending dose, phase 1
study in patients with IPF, PRM-151 was safe
and well tolerated, and demonstrated a trend
towards improvement in pulmonary function
and circulating levels of surfactant protein D
and VEGF at 8 weeks [58]. PRM-151 is currently




Ongoing adaptive immune response against
autoantigens is thought to play an important
role in disease progression in some IPF patients
[59]. Type V collagen (col(V)) is a minor
collagen normally sequestered within the lung
interstitium and, therefore, hidden from the
immune system. Lung injury may lead to
col(V) exposure, making it available for
activation of an autoimmune response [60]. A
sustained autoimmune response against col(V),
which is present in approximately 50% of
patients, may result in abnormal lung
remodeling and fibrotic changes [61, 62]. In a
recently published phase 1 study
(ClinicalTrials.gov identifier, NCT01199887),
an orally available compound that induces
immune tolerance to col(V) (IW001;
ImmuneWorks, Inc, Indianapolis, IN, USA),
was safe and well tolerated, and showed a
trend towards stabilization of FVC and
metalloproteinase 7 levels in anti-col(V) Ab?
patients with IPF [63]. Further study with
col(V) oral immunotherapy is warranted to
confirm the therapeutic effect of IW001 in
patients with IPF.
TD139
Galectin-3, a member of the galectin family of
galactoside binding lectins, has been shown to
play a central role in fibrosis development and
progression through the activation of
macrophages and recruitment and activation
of myofibroblasts [64]. TD139 (Galecto Biotech
AB, Copenhagen, Denmark) is a highly potent,
specific inhibitor of the galactoside binding
pocket of galectin-3 formulated for inhalation.
Safety and tolerability of TD139 in patients with
IPF are currently being evaluated in a phase 1b/
2a trial (ClinicalTrials.gov identifier,
NCT02257177).
BMS-986020
Lysophosphatidic acid (LPA) is a
well-recognized mediator of wound healing
and tissue fibrosis [65], and LPA receptor 1
(LPA1) appears to contribute to the
development of IPF by inducing epithelial cell
apoptosis, fibroblast recruitment and vascular
leak [66]. The safety and efficacy of BMS-986020
(Bristol-Myers Squibb, New York, NY, USA), a
high-affinity, selective, small-molecule
antagonist of LPA1 in patients with IPF is
currently being assessed in a phase 2 trial
(ClinicalTrials.gov identifier, NCT01766817).
FG-301
It is a humanized monoclonal antibody directed
against connective tissue growth factor (CTGF),
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a key mediator of tissue remodeling and fibrosis.
Safety and tolerability of FG-3019 (FibroGen,
Inc, San Francisco, CA, USA) in patients with
IPF have been evaluated in an exploratory phase
2 dose escalation open-label study. Data of the
first dose cohort (15 mg/kg intravenous every
3 weeks) have been published in the form of an
abstract [67]. Fifty-three subjects were enrolled
and treated; 39 of them completed the
treatment period and 14 withdrew. FG-3019
was safe and well tolerated. In addition, the
majority of patients [27 of the 38 (71%) who
had acceptable data at week 48] experienced
improvement or\5% loss in FVC % predicted at
week 48. Moreover, improved or stable lung
fibrosis as measured by quantitative HRCT was
observed in more than half of subjects. On
average, patients with improved or
stable fibrosis also had improved pulmonary
function. Based on these encouraging data, a
randomized placebo-controlled phase 2 trial in
patients with IPF is currently being conducted
(ClinicalTrials.gov identifier, NCT01890265).
Lebrikizumab
Lebrikizumab (Hoffmann-La Roche, Basel,
Switzerland) is a humanized monoclonal
antibody against interleukin (IL)-13, a Th2
cytokine that is found at increased levels in
the lungs of patients with IPF [68]. In vitro,
IL-13 stimulates fibroblast proliferation and
induces CCL6/C10, a chemotactic factor for
mononuclear phagocytes, which in turn are an
important source of growth factors that regulate
ECM synthesis [69]. In vivo, IL-13
overexpression results in increased fibrosis in
mice in response to bleomycin [69].
Lebrikizumab (as both monotherapy and as
combination therapy with pirfenidone
background therapy) is currently being tested
in patients with IPF in a phase 2b study
(ClinicalTrials.gov identifier, NCT01872689)
with results expected in late 2016.
Tralokinumab
Tralokinumab (MedImmune LLC, Gaithersburg,
MD, USA) is a human IL-13-neutralizing
immunoglobulin G4 monoclonal antibody.
Murray and colleagues have recently shown
that the IL-13 pathway is significantly
enhanced in biopsy samples from IPF patients
who exhibit a rapidly progressing disease course
compared with patients with a slower rate of
lung function loss. In addition, they also
demonstrated that inhibition of human IL-13
with tralokinumab attenuated established lung
fibrosis and promoted alveolar epithelial repair
processes in a humanized severe combined
immunodeficiency (SCID) mouse model of IPF
[70]. Safety, tolerability and effectiveness of
multiple doses of tralokinumab are being
evaluated in phase 2 studies (ClinicalTrials.gov
identifiers, NCT01629667 and NCT02036580,
the latter only in Japanese patients), which are
ongoing yet currently not recruiting patients.
SAR156597
IL-4, a cytokine structurally related to IL-13, has
also been implicated in the abnormal
proliferation of fibroblasts that characterizes
IPF [71]. In addition, targeting the IL-13 and
IL-4 receptors has been shown to modulate the
abnormal proliferative properties of human
lung fibroblasts [72]. SAR156597 (Sanofi S.A.,
Paris, France) is a humanized bispecific
antibody that neutralizes both IL-4 and IL-13
circulating cytokines. In patients with IPF,
SAR156597 has been shown to be generally
safe and well tolerated [73] The safety and
efficacy of two dose levels of SAR156597
administered subcutaneously during 52 weeks
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in patients with IPF are currently being tested in
a phase 2 study (ClinicalTrials.gov identifier,
NCT02345070).
Simtuzumab
Simtuzumab (Gilead Sciences, Foster city, CA,
USA) is a humanized monoclonal antibody
against lysyl oxidase-like 2 (LOXL2), an
enzyme that catalyzes covalent cross linking of
ECM molecules, including collagen fibers.
LOXL2 protein expression is observed in the
fibroblastic foci and collagenous regions of
diseased IPF lung tissue [74] and serum LOXL2
levels are associated with increased risk for IPF
disease progression [75]. Moreover, in the
bleomycin-induced mouse model of
pulmonary fibrosis, inhibition of LOXL2
resulted in a marked reduction in activated
fibroblasts, decreased production of growth
factors and cytokines and decreased TGF-b
pathway signaling [74]. The safety and efficacy
of simtuzumab in patients with IPF are being
evaluated in a phase 2 study (ClinicalTrials.gov
identifier, NCT01769196), which is ongoing,
but currently not recruiting patients.
STX-100
STX-100 (Biogen, Weston, MA, USA) is a
humanized monoclonal antibody against the
integrin avb6, which functions as a key
mediator of TGF-b activation and plays an
important functional role in promoting and
maintaining fibrogenesis and epithelial injury
[76]. In murine bleomycin-induced pulmonary
fibrosis, partial inhibition of avb6 effectively
inhibits TGF-b activation, epithelial injury, and
tissue fibrosis [77]. The safety and tolerability of
subcutaneously administered multiple,
escalating doses of STX-100 in patients with
IPF are being evaluated in a phase 2 study,
which is currently recruiting participants
(ClinicalTrials.gov identifier, NCT01371305).
CONCLUSIONS
IPF is a progressive and almost invariably fatal
disease. Over the last decade, our knowledge of
the mechanisms involved in disease
pathobiology has substantially improved and
this had allowed a number of clinical trials of
pharmacological interventions to be
undertaken and completed. This massive effort
of the medical and industry community has
produced the approval of two drugs of
comparable safety and efficacy profile,
pirfenidone and nintedanib, which will soon
become standard of care worldwide (Table 2).
Yet, this is only the beginning as neither
pirfenidone nor nintedanib is a cure for IPF,
neither drug improves lung function and most
patients continue to progress while on
treatment. These limitations notwithstanding,
the concerted effort by the scientific,
professional and patient community as well as
the pharmaceutical industry has the potential
to finally develop a real cure for patients
suffering from this devastating disease.
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Table 2 Pirfenidone versus nintedanib: justiﬁcation and implementation considerations according to the 2015 Idiopathic
Pulmonary Fibrosis guidelines
Pirfenidone Nintedanib
High value on the potential beneﬁt on patient-reported
outcomes such as disease progression as measured by rate
of FVC decline and mortality
High value on the potential beneﬁt on patient-reported
outcomes such as disease progression as measured by rate
of FVC decline and mortality
Lower value on potentially signiﬁcant adverse events and
cost of treatment
Lower value on potentially signiﬁcant adverse events and
cost of treatment
Pooled analysis of the CAPACITY and ASCEND trials
suggested improved mortality (relative risk: 0.70; 95% CI:
0.47–1.02; moderate conﬁdence)
Pooled analysis of the TOMORROW and INPULSIS trials
suggested improved mortality (relative risk: 0.70; 95% CI:
0.47–1.03; moderate conﬁdence)
Pirfenidone treatment was associated with increased rates of
photosensitivity (high conﬁdence), fatigue (moderate
conﬁdence), stomach discomfort (moderate conﬁdence),
and anorexia (high conﬁdence). Patients should be
informed and educated on all potential adverse effects
Signiﬁcantly more patients treated with nintedanib reported
adverse events (high conﬁdence), but not serious adverse
events (high conﬁdence). Patients should be informed and
educated on all potential adverse effects
Pirfenidone is a very costly intervention and this should be
considered in the decision-making process
Costs of nintedanib should be considered in the
decision-making process and this may limit its feasibility
and use
It is unknown whether the therapeutic beneﬁts would differ
in patients with a more severe lung function impairment
(FVC\50%) or in those with other comorbidities
It is unknown whether the therapeutic beneﬁts would differ
in patients with a more severe lung function impairment
(FVC\50%) or in those with other comorbidities
Optimal duration of treatment and treatment effect
duration while on therapy are unknown
Optimal duration of treatment and treatment effect
duration while on therapy are unknown
Adapted from [25]
CI Conﬁdence interval, FVC Forced vital capacity
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